Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Long non-coding RNAs (lncRNAs) are crucial in lung adenocarcinoma progression.
• Differential expression of lncRNAs and genes is observed in lung adenocarcinoma.

Purpose of the Study:

• Identify cancer-related lncRNAs and genes in lung adenocarcinoma.
• Investigate the functional role of LINC00628 and LAMA3 in lung adenocarcinoma.
• Elucidate the mechanism of LINC00628 in regulating LAMA3 expression and its impact on lung adenocarcinoma progression and drug resistance.

Main Methods:

• Screening for differentially expressed lncRNAs in lung adenocarcinoma.
• Validation of LINC00628 and LAMA3 expression in patient tissues.
• Functional assays involving LINC00628 overexpression/silencing and 5-azacytidine (5-Aza) treatment.
• Analysis of DNA methyltransferase (DNMT) recruitment and LAMA3 promoter methylation.
• In vivo experiments in nude mice to assess tumor growth and drug resistance.

Main Results:

• LINC00628 was overexpressed, while LAMA3 was underexpressed in lung adenocarcinoma.
• LINC00628 silencing reduced proliferation, migration, invasion, and vincristine (VCR) resistance.
• 5-Aza treatment led to LAMA3 demethylation and opposite cellular effects compared to LINC00628 silencing.
• LINC00628 recruited DNMT1, DNMT3A, and DNMT3B to methylate the LAMA3 promoter.
• LINC00628 silencing and 5-Aza treatment inhibited tumor growth and VCR resistance in vivo.

Conclusions:

• LINC00628 promotes lung adenocarcinoma by epigenetically silencing LAMA3 via DNMT recruitment.
• LINC00628 silencing inhibits lung adenocarcinoma progression and enhances sensitivity to VCR.
• LINC00628 represents a potential therapeutic target for VCR-resistant lung adenocarcinoma.